The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial

Article English OPEN
Khawaja, Muhammed ; Wang, Duolao ; Pocock, Stuart ; Redwood, Simon ; Thomas, Martyn (2014)
  • Publisher: BioMed Central
  • Journal: Trials, volume 15 (eissn: 1745-6215)
  • Related identifiers: doi: 10.1186/1745-6215-15-300, pmc: PMC4132914
  • Subject: Transcatheter aortic valve implantation | wg_20 | Medicine (miscellaneous) | Percutaneous coronary intervention | Aortic stenosis | Coronary | Study Protocol | wg_200 | Pharmacology (medical)

Background\ud \ud Current guidelines recommend treatment of significant coronary artery disease by concomitant coronary artery bypass grafting (CABG) in patients undergoing surgical aortic valve replacement. However there is no consensus as to how best to treat coronary disease in high-risk patients requiring transcatheter aortic valve implantation (TAVI).\ud \ud Methods/Design\ud \ud The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial is a randomized, controlled open-label trial of 310 patients randomized to treatment of significant coronary artery disease by percutaneous coronary intervention (PCI - test arm) or no PCI (control arm). Significant coronary disease is defined as ≥1 lesion of ≥70% severity in a major epicardial vessel or 50% in a vein graft or protected left main stem lesion. The trial tests the hypothesis that the strategy of performing pre-TAVI PCI is non-inferior to not treating such coronary stenoses with PCI prior to TAVI, with a composite primary outcome of 12-month mortality and rehospitalization. Secondary outcomes include efficacy end-points such as 30-day mortality, safety endpoints including bleeding, burden of symptoms, and quality of life (assessed using the Seattle Angina Questionnaire and the Kansas City Cardiomyopathy Questionnaire).\ud \ud In conclusion, we hope that using a definition of coronary artery disease severity closer to that used in everyday practice by interventional cardiologists - rather than the 50% severity used in surgical guidelines - will provide robust evidence to direct guidelines regarding TAVI therapy and improve its safety and efficacy profile of this developing technique.\ud \ud Trial registration\ud \ud ISRCTN75836930, http://www.controlled-trials.com/ISRCTN75836930 (registered 19 November 2011).
  • References (35)
    35 references, page 1 of 4

    1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002, 106:3006-3008.

    2. Ortlepp JR, Schmitz F, Bozoglu T, Hanrath P, Hoffmann R: Cardiovascular risk factors in patients with aortic stenosis predict prevalence of coronary artery disease but not of aortic stenosis: an angiographic pair matched case-control study. Heart 2003, 89:1019-1022.

    3. Dworakowski R, MacCarthy PA, Monaghan M, Redwood S, El-Gamel A, Young C, Bapat V, Hancock J, Wilson K, Brickham B, Wendler O, Thomas MR: Transcatheter aortic valve implantation for severe aortic stenosis-a new paradigm for multidisciplinary intervention: a prospective cohort study. Am Heart J 2010, 160:237-243.

    4. Masson J-B, Lee M, Boone RH, Ali Al A, Bugami Al S, Hamburger J, John Mancini GB, Ye J, Cheung A, Humphries KH, Wood D, Nietlispach F, Webb JG: Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2010, 76:165-173.

    5. Dewey TM, Brown DL, Herbert MA, Culica D, Smith CR, Leon MB, Svensson LG, Tuzcu M, Webb JG, Cribier A, Mack MJ: Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg 2010, 89:758-767. discussion 767.

    6. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF: Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? a clinical morphologic study. Clin Cardiol 1991, 14:995-999.

    7. Gerckens U, Latsios G, Mueller R, Buellesfeld L, Sauren B, Iversen S, Felderhof T, Grube E: Left main PCI after trans-subclavian CoreValve implantation: successful outcome of a combined procedure for management of a rare complication. Clin Res Cardiol 2009, 98:687-690.

    8. Geist V, Sherif MA, Khattab AA: Successful percutaneous coronary intervention after implantation of a CoreValve percutaneous aortic valve. Catheter Cardiovasc Interv 2009, 73:61-67.

    9. Sohal M, Stevens K, Rajani R, Khawaja MZ, De Belder A, Hildick-Smith D: Percutaneous coronary intervention of the right coronary artery following deployment of the CoreValve® revalving system. EuroIntervention 2009, 5:5. online [http://www.pcronline.com/eurointervention/23rd_issue/case4/]. 'doi:10.1074/jbc.R4000028200' or 'e8278'.

    10. Leon MB, Kodali S, Williams M, Oz M, Smith C, Stewart A, Schwartz A, Collins M, Moses JW: Transcatheter aortic valve replacement in patients with critical aortic stenosis: rationale, device descriptions, early clinical experiences, and perspectives. Semin Thorac Cardiovasc Surg 2006, 18:165-174.

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark